|
See related Myfortic information |
|
|
|
Manufacturer |
Novartis |
|
Distributor |
Zuellig |
|
Contents |
Mycophenolate Na |
|
Indications |
In combination w/ ciclosporin & corticosteroids for the prophylaxis of acute transplant rejection in adult patients receiving allogeneic renal transplants.
Click to view Myfortic detailed prescribing infomation |
|
Dosage |
720 mg bid (total daily dose: 1,440 mg). Must be initiated & maintained by transplant specialists.
Click to view Myfortic detailed prescribing infomation |
|
Overdosage |
View Myfortic overdosage for action to be taken in the event of an overdose. |
|
Administration |
May be taken with or without food (Swallow whole, do not chew/crush.). |
|
Contraindications |
Pregnancy.
Click to view Myfortic detailed prescribing infomation |
|
Special Precautions |
Increased risk of developing lymphomas & other malignancies, particularly of the skin. Oversuppression of immune system increases susceptibility to infection. Active severe GI disease. Perform complete blood counts regularly to monitor neutropenia. Lactation.
Click to view Myfortic detailed prescribing infomation |
|
Adverse Drug Reactions |
Constipation, nausea, diarrhoea, UTI & leucopenia. CMV infections, upper resp tract & skin infections, sore, unexpected heartburn & unexpected bruising & bleeding.
View ADR Monitoring Form |
|
Drug Interactions |
Cholestyramine & drugs that interfere w/ enterohepatic circulation. Azathioprine, aciclovir, & Mg- & Al(OH)3-containing antacids.
View more drug interactions with Myfortic |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
Storage |
View Myfortic storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Myfortic description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Myfortic mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Myfortic gastro-resistant tablet |
|
Myfortic 180 mg x 120's |
 |
|
|
Myfortic gastro-resistant gastro-resistant capsule |
|
|
|
Manufacturer: |
Novartis |
|
Distributor: |
Zuellig
|
|
|
|
